Case Report: Dacomitinib May Not Benefit Patients Who Develop Rare Compound Mutations After Later-Line Osimertinib Treatment

Overview of attention for article published in Frontiers in oncology, April 2021

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 12 Dimensions

Readers on

mendeley: 14 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 12 publications that cite this research output.

12

The most recent citing publications are shown below. View all 12 publications that cite this research output on Dimensions.

Dacomitinib overcomes acquired resistance to osimertinib in advanced NSCLC patients with EGFR L718Q mutation: A two-case report

Article in Medicine (July 2024)

The treatment of patients with non-small cell lung cancer carrying uncommon EGFR mutations, HER2 mutations, or brain metastases: a systematic review of pre-clinical and clinical findings for dacomitinib

Article in Translational Cancer Research (August 2023)

Rare case of de novo EGFR L718V mutation-positive non-small cell lung cancer successfully treated with afatinib

Article in Current Problems in Cancer Case Reports (June 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.